| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.1 | 0.06 |
| mRNA | vorapaxar | CTRPv2 | pan-cancer | AAC | 0.075 | 0.06 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | 0.083 | 0.07 |
| mRNA | GDC-0449 | GDSC1000 | pan-cancer | AAC | 0.067 | 0.07 |
| mRNA | ML006 | CTRPv2 | pan-cancer | AAC | 0.072 | 0.07 |
| mRNA | Compound 1541A | CTRPv2 | pan-cancer | AAC | 0.076 | 0.07 |
| mRNA | IPA-3 | GDSC1000 | pan-cancer | AAC | -0.06 | 0.07 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | -0.07 | 0.07 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.073 | 0.07 |
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | -0.059 | 0.07 |